WHO Hub Berlin Highlights 2025 Achievements in Pandemic Intelligence
The WHO Hub for Pandemic and Epidemic Intelligence in Berlin released its 2025 Annual Report, detailing advancements in AI, data science, and genomics for global health threat detection. The report highlights collaboration with over 160 Member States and 190 partners to enhance pandemic preparedness.
HHS OIG: Nursing Homes Misdiagnosed Residents to Mask Antipsychotic Drug Misuse
The HHS Office of Inspector General (OIG) issued a report finding that nursing homes inappropriately diagnosed residents with schizophrenia to mask the misuse of antipsychotic drugs and artificially inflate their star ratings. The OIG recommends that CMS expand its use of data to monitor these diagnoses and increase efforts to inform residents and families about antipsychotic drug use.
HHS OIG: Indiana Nursing Homes Generally Complied with Federal Background Check Requirements
The HHS Office of Inspector General (OIG) reported that Indiana nursing homes generally complied with federal requirements for employee background checks. Out of 825 employees reviewed, only 13 lacked completed background checks, and none had disqualifying offenses.
HHS OIG: Nursing Homes Misuse Antipsychotics on Dementia Residents
The HHS Office of Inspector General (OIG) issued a report finding that nursing homes inappropriately administer antipsychotic drugs to residents with dementia, often to manage behavior for staff benefit, despite FDA warnings of increased mortality risk. The report recommends CMS develop resources and increase transparency to reduce misuse and improve dementia care.
ANSM Security Alert for EdgeSuite Software and EdgeLab Module
The French National Agency for Medicines and Health Products Safety (ANSM) has issued a security alert regarding the EdgeSuite software and EdgeLab module from In Log. Affected medical analysis laboratories have been notified directly by the company.
Product Recall: Artis PL E and Artis Symbiose Intraocular Lenses
The French National Agency for the Safety of Medicines and Health Products (ANSM) has announced a product recall for Artis PL E and Artis Symbiose intraocular lenses manufactured by Cristalens Industrie. This safety action, registered under number R2606056, requires healthcare facilities to take immediate action regarding the affected lots.
Curosurf Safety Information and Lot Recall
The French drug agency ANSM, in agreement with Laboratoire Chiesi SAS, has initiated a recall of one lot (Lot 1204229, Exp 04/2026) of Curosurf 120 mg/1.5 ml suspension for endotracheobronchial instillation. This precautionary measure follows a deviation observed during environmental monitoring at the production site.
Kentucky Board of Pharmacy Suspends Wilson Family Pharmacy
The Kentucky Board of Pharmacy has issued an emergency suspension order for Wilson Family Pharmacy INC and pharmacist owner Jigna G Patel, effective August 15, 2025. The suspension follows preliminary findings of serious violations, including inadequate security of prescription drugs and dispensing medication without valid prescriptions, posing an imminent risk to public health.
KY Board Fines Med Save Pharmacy $5,000, Revokes Licenses
The Kentucky Board of Pharmacy has fined Med Save Pharmacy $5,000 and revoked its licenses following medication errors that led to the hospitalization of three pediatric patients. The pharmacy compounded misbranded and adulterated clonidine suspensions, violating multiple state statutes and regulations.
KY Board of Pharmacy Alert on Compounded GLP-1/GIP Drugs
The Kentucky Board of Pharmacy issued an alert regarding the compounding and dispensing of GLP-1/GIP drugs like semaglutide and tirzepatide from 503B outsourcing facilities. The alert clarifies when such compounding is permissible, referencing FDA guidance and court decisions concerning drug shortage lists and enforcement discretion.
Kentucky Pharmacy Technician Regulations Updated
The Kentucky Board of Pharmacy has updated regulations concerning pharmacy technicians, specifically 201 KAR 2:045 and 2:165. These amendments clarify technician roles, delegate new responsibilities to certified technicians, and centralize initial application requirements, including mandatory registration for an NABP e-profile.
WV Board of Pharmacy CSMP Modernization to RxGov System
The West Virginia Board of Pharmacy is modernizing its Controlled Substances Monitoring Program (CSMP) by transitioning from the CSAPP platform to the RxGov system. This upgrade aims to improve performance, data quality, and reporting capabilities. Key transition dates are outlined, with a full cutover expected in early March 2026.
DEA Extends Telemedicine Flexibilities for Controlled Medications
The DEA, in conjunction with HHS, has extended current telemedicine flexibilities for prescribing controlled medications through December 31, 2026. This allows DEA-registered practitioners to remotely prescribe Schedule II-V controlled medications, including certain narcotic medications for opioid use disorder treatment, without a prior in-person evaluation.
WV Board of Pharmacy Warns of Phone Scam Targeting Licensees
The West Virginia Board of Pharmacy has issued a warning regarding a phone scam targeting its licensees. Scammers are impersonating Board investigators, claiming disciplinary action and attempting to solicit payment over the phone. The Board reminds licensees that it will never request payment in lieu of an investigation.
WV Pharmacy Board Adopts CDC COVID-19 Vaccine Recommendations
The West Virginia Board of Pharmacy has adopted the CDC's recommendations for the 2025-2026 COVID-19 vaccines. This guidance allows pharmacists, technicians, and interns to administer vaccines to individuals aged 3 years and older, based on individual decision-making and CDC risk factor guidelines.
Louisiana Board of Pharmacy Office Closure due to Hurricane Ida
The Louisiana Board of Pharmacy announced an extension of its office closure due to Hurricane Ida, now through September 5, 2021. The office will remain closed to visitors due to staffing impacts from COVID-19, with materials to be deposited via mail slot or submitted electronically.
Louisiana Board of Pharmacy Office Closure Due to Hurricane Nicholas
The Louisiana Board of Pharmacy announced the closure of its state office on September 15, 2021, due to anticipated severe weather from Hurricane Nicholas. The office is expected to reopen for business, though not for visitors, on September 16, 2021, unless the closure order is extended.
Louisiana Board of Pharmacy Office Closure Due to COVID-19
The Louisiana Board of Pharmacy announced its office is closed to visitors effective immediately due to COVID-19 illness impacting staff levels. Licensees and applicants are directed to use mail or email for submissions and inquiries, as phone lines are on auto-attendant.
Louisiana Board of Pharmacy Office Reopens to Business, Remains Closed to Public
The Louisiana Board of Pharmacy has reopened its office for business following Hurricane Ida closures. However, due to insufficient staffing, the office remains closed to public visitors. Deliveries can be made via the mail slot, and inquiries should be directed to the general email address.
Louisiana Pharmacy Credential Renewal Notice
The Louisiana Board of Pharmacy has issued a notice regarding the credential renewal cycle for pharmacists and pharmacies. The renewal period for licenses and permits will be open from November 1 to December 31, 2021, with options for online or paper applications.
Florida MQA releases 2025-26 Q2 performance report
Florida MQA releases 2025-26 Q2 performance report
Contract Award for Pharmacy Professionals Recovery Services
The Mississippi Board of Pharmacy has announced a contract award for pharmacy professionals recovery services. This notice serves to inform stakeholders about the selection of a service provider to offer support and resources for pharmacy professionals facing substance abuse or other challenges.
Mississippi Board of Pharmacy Final Rule Effective
The Mississippi Board of Pharmacy has filed a final administrative rule with the Secretary of State. This rule will become effective on March 13, 2026, impacting healthcare providers within the state.
MS Board of Pharmacy Resolution for State of Emergency Ice Storm
The Mississippi Board of Pharmacy has issued a resolution acknowledging the state of emergency due to an ice storm. This resolution outlines temporary measures and guidance for pharmacies to ensure continued patient access to medications during the emergency period.
MS Board of Pharmacy Accepting Applications for 2 Positions
The Mississippi Board of Pharmacy is seeking applications for two positions: a Compliance Agent and a Staff Attorney. The job posting for the Compliance Agent will remain open until February 4, 2026, and includes statewide field work. The Staff Attorney position requires at least five years of legal experience and familiarity with administrative law.
MEAC Medical Equipment Advisory Committee Meeting Announcement
The Mississippi Board of Pharmacy has announced a meeting for the Medical Equipment Advisory Committee (MEAC) on December 2, 2025. The meeting will cover topics related to medical equipment and is scheduled to take place at the Board's office in Jackson, Mississippi.
Specialized Bicycle Components Recalls Turbo Como SL Electric Bicycles for Fall Hazard
Specialized Bicycle Components is recalling approximately 5,720 Specialized Turbo Como SL electric bicycles due to a fall hazard caused by potential fatigue cracks in the fork steerer tube. Consumers are advised to contact Specialized for a repair.
Electrolux Frigidaire Gas Ranges Recalled Due to Burn Hazard
Electrolux Group is recalling approximately 174,800 Frigidaire gas ranges due to a delayed ignition hazard with the oven's bake burner. The recall affects specific models sold between June 2025 and January 2026. Consumers are advised to stop using the ovens immediately and contact Electrolux for a free repair.
Amazon Basics Folding Knives Recalled Due to Laceration Hazard
Amazon is recalling approximately 2,840 Amazon Basics Camping Folding Pocket Knives due to a laceration hazard caused by a failure in the folding mechanism. Consumers are advised to stop using the knives immediately and register for a full refund.
Tainoki Fine Furniture Recalls Office Chairs Due to Fall Hazard
Tainoki Fine Furniture is recalling approximately 2,200 swivel office chairs due to a fall hazard caused by the chair's base bending. The CPSC is advising consumers to stop using the chairs immediately and seek a full refund. The recall affects chairs sold at HomeGoods stores nationwide.
Lifetime Brands Recalls BUILT LUUM Tumblers Due to Choking and Battery Ingestion Hazards
Lifetime Brands is recalling approximately 11,000 BUILT LUUM Light Up Tumblers due to a risk of choking and battery ingestion hazards. The LED light-up component can detach, posing a danger to young children. Consumers are urged to stop using the recalled tumblers immediately and contact Lifetime Brands for a full refund.
Goregent infant walkers recalled due to fall hazard, risk of injury or death
Goregent infant walkers recalled due to fall hazard, risk of injury or death
Aisstxoer Adult Bicycle Helmets Recalled Due to Injury Risk
The CPSC announced the recall of approximately 200 Aisstxoer adult bicycle helmets sold on Amazon.com due to a violation of the mandatory safety standard for bicycle helmets, posing a risk of serious injury or death from head injury. Consumers are advised to stop using the helmets and contact the seller for a full refund.
Wagner Steamers Recalled for Burn Hazard
Wagner Spray Tech is recalling approximately 700,000 units of its 900 Series Power Steamers due to a burn hazard caused by the hose getting excessively hot and expelling hot water. The CPSC is working with the company to offer a free repair kit to affected consumers.
DEA Warns About Methamphetamine and Street Names
The DEA issued a public safety alert warning about methamphetamine, listing its various street names such as Crank, Crystal, and Ice. The alert directs readers to a DEA factsheet for more information on the drug and its effects.
DEA Public Safety Alert: Fentanyl Affects All Communities
The DEA issued a public safety alert via Twitter, emphasizing that fentanyl affects all communities regardless of race, age, or economic status. The alert, from DEA SAC D. Olesky, reiterates the DEA's goal of a fentanyl-free America and mentions a joint effort with Aurora Police to combat drug trafficking.
DEA Notice: Sterling Wisconsin LLC Controlled Substances Application
The Drug Enforcement Administration (DEA) has published a notice regarding an application from Sterling Wisconsin, LLC to be registered as a bulk manufacturer of various controlled substances, including Schedule I and II drugs. The public has until May 18, 2026, to submit comments or objections.
DEA: Application to Import Controlled Substances by Patheon API Services
The Drug Enforcement Administration (DEA) has published a notice regarding an application from Patheon API Services, Inc. to be registered as an importer of controlled substances, including Dimethyltryptamine, Psilocybin, Psilocyn, Amphetamine, and Methadone. The application is for research and development purposes.
DEA Notice: SpecGx LLC Controlled Substances Importer Application
The Drug Enforcement Administration (DEA) has published a notice regarding an application from SpecGx LLC to be registered as an importer of controlled substances, including Phenylacetone, Coca Leaves, Thebaine, Opium, Poppy Straw Concentrate, and Tapentadol. Interested parties can submit comments or objections by April 20, 2026.
DEA Application for Bulk Manufacturer of Controlled Substances: Siegfried Grafton, Inc.
The Drug Enforcement Administration (DEA) has published a notice regarding an application from Siegfried Grafton, Inc. to be registered as a bulk manufacturer of various controlled substances, including Schedule I and II drugs. The application is open for public comment and objections until May 18, 2026.
DEA Notice: Importer Controlled Substances Application - Siegfried Grafton, Inc.
The Drug Enforcement Administration (DEA) has published a notice regarding an application from Siegfried Grafton, Inc. to be registered as an importer of Schedule I controlled substances, including Gamma Hydroxybutyric Acid and Marihuana Extract. The public comment period for this application closes on April 20, 2026.
DEA Notice: Pisgah Laboratories Inc Importer Application
The Drug Enforcement Administration (DEA) has issued a notice regarding an application from Pisgah Laboratories Inc. to be registered as an importer of controlled substances, specifically Phenylacetone, Ecgonine, Thebaine, and Tapentadol. The public comment period for this application closes on April 20, 2026.
DEA Notice: United States Pharmacopeial Convention Application to Import Controlled Substances
The Drug Enforcement Administration (DEA) has published a notice regarding an application from the United States Pharmacopeial Convention to be registered as an importer of various controlled substances, including Schedule I and II drugs. The public has until April 20, 2026, to submit comments or request a hearing.
National Institute of Diabetes and Digestive and Kidney Diseases; Closed Meeting Notice
The National Institutes of Health (NIH) has published a notice regarding a closed meeting for the National Institute of Diabetes and Digestive and Kidney Diseases. The meeting is scheduled for July 1, 2026. This notice serves as an informational announcement.
Center for Scientific Review; Notice of Closed Meetings
The National Institutes of Health (NIH) Center for Scientific Review has announced upcoming closed meetings. These meetings are scheduled for April 16, 2026, and involve discussions related to grant applications and review processes.
FDA Proposed Collection of Information on Premarket Notifications
The FDA has proposed a new collection of information regarding premarket notifications. This is a request for comments on the proposed collection, with a deadline of May 18, 2026.
FDA Draft Guidance on New Approach Methodologies in Drug Development
The FDA has issued draft guidance for industry on the use of New Approach Methodologies (NAMs) in drug development. This guidance provides recommendations for sponsors on how to incorporate NAMs into their regulatory submissions. The comment period for this draft guidance closes on May 18, 2026.
FDA Guidance on Pyrogen and Endotoxin Testing
The FDA has issued guidance for biological product, drug, and device firms regarding pyrogen and endotoxin testing. This document provides recommendations based on current FDA thinking concerning USP and AAMI standards for bacterial endotoxin and pyrogen tests.
FDA Warning Letter to Vedic Lifesciences for GLP Violations
The FDA issued a warning letter to Vedic Lifesciences Pvt. Ltd. for violations of Good Laboratory Practice (GLP) regulations during the inspection of nonclinical laboratory studies. The company failed to prepare accurate final reports for investigational drug studies, misrepresenting testing facility and personnel information.
WTC Health Program Denies Petition for Anti-GBM Glomerulonephritis
The Centers for Disease Control and Prevention (CDC) has issued a notice denying Petition 026 for the addition of Anti-Glomerular Basement Membrane (Anti-GBM) Glomerulonephritis to the World Trade Center (WTC) Health Program. The agency found insufficient evidence to support its inclusion.
FDA Document on Biochemical Changes in Red Blood Cells
The FDA has posted a document concerning biochemical changes in red blood cells. The document is available for review on Regs.gov, though specific details are restricted due to copyright.
FDA Medical Device User Fee Rates for FY 2024
The Food and Drug Administration (FDA) has posted the Medical Device User Fee rates for Fiscal Year 2024. This notice provides the updated fee schedule for medical device manufacturers.
FDA Economic Analysis of CDRH Submission Requirements
The FDA has published an economic analysis concerning the submission requirements for the Center for Devices and Radiological Health (CDRH). This analysis provides insights into the economic impact of these requirements on medical device manufacturers.
FDA PRIA Reference Data
The FDA has published reference data related to the Prescription Drug User Fee Act (PRIA) for May 2024. This notice includes national employment data relevant to PRIA submissions. It serves as an informational update for regulated entities.
FDA Guidance on Physicochemical Characterization of Topical Drug Products
The FDA has issued final guidance for industry on the physicochemical and structural characterization of topical drug products submitted in Abbreviated New Drug Applications (ANDAs). This guidance, which finalizes a draft from October 2022, provides recommendations to support bioequivalence demonstrations for generic topical products.
FDA PRIA Reference SBA Size Standards Update
The FDA has posted an update regarding the Presolicitation Information and Analysis (PRIA) Reference, specifically concerning Small Business Administration (SBA) size standards. This notice updates the reference document used by the agency for certain regulatory processes.
FDA Guidance on EpCAM-Positive Cell Reduction by Filters
The FDA has issued guidance concerning the reduction of EpCAM-positive cells by filters. This document provides information relevant to drug manufacturers and medical device makers.
FDA Radiology Devices Classification Regulatory Analysis
The FDA has published a regulatory analysis concerning the classification of radiology devices. This notice provides an overview of the agency's approach to classifying these medical devices, offering clarity to manufacturers and stakeholders.
Angiographic Catheters Recalled Due to Molded Hub Non-Conformance
Health Canada has issued a recall for AngioDynamics' Soft-Vu and Accu-Vu 4 FR Angiographic Catheters due to a molded hub non-conformance. The defect may prevent guidewire passage, though no injuries have been reported in Canada. Healthcare providers should contact the manufacturer for information.
Health Canada Recalls Vacuum Bag SU Large Due to Leakage Risk
Health Canada has issued a Type II recall for the Milestone S.R.L. Vacuum Bag SU Large due to a risk of leakage from the specimen container. Healthcare providers are advised to contact the manufacturer for additional information.